[Ct findings of drug-induced pneumonitis--characteristic CT findings by histological group and subgroup].
We examined the chest CT results of 27 cases of drug-induced pneumonitis. We classified the subjects into 3 groups in accordance with the clinicopathological findings: eosinophilic pneumonia (EP) group (5 cases), diffuse alveolar damage (DAD) group (3 cases), and interstitial pneumonia (IP) group (19 cases). We evaluated the CT findings in each group, and made a further subclassification. In the EP group, the CT findings were subdivided into two, namely, type A, with diffuse distribution consistent with CT findings of acute eosinophilic pneumonia; and type B, with subpleural distribution consistent with chronic eosinophilic pneumonia. In the DAD group, the CT findings were diffuse distribution of mixed ground-glass attenuation and air-space consolidation, with or without traction bronchiectasis, and without shrinking of the lung. In the IP group, the CT findings were subdivided into 3, namely type A, with ground-glass attenuation dominant, without traction bronchiectasis or shrinking of the lung, consistent with the CT findings of IP without fibrosis; type B, with air-space consolidation dominant, with traction bronchiectasis and shrinking of the lung, consistent with the CT findings of IP with fibrosis; and type C with multiple nodules dominant. Radiological differentiation of the DAD group from IP-type B may be possible by the presence or absence of a shrinking lung pattern. We concluded that the subgroups of CT findings in drug-induced pneumonitis may be useful for diagnosis of this disease, and for prognosis.
Matsushima
Hidekazu
H
Department of Respiratory Medicine, Saitama Cardiovascular and Respiratory Center, Saitama, Japan.
Takayanagi
Noboru
N
Tokunaga
Daido
D
Maeno
Yuri
Y
Sato
Nagato
N
Kurashima
Kazuyoshi
K
Ubukata
Mikio
M
Yanagisawa
Tsutomu
T
Sugita
Yutaka
Y
Kawabata
Yoshinori
Y
Kanazawa
Minoru
M
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000890:Anti-Infective Agents / Q000009:adverse effects; D018501:Antirheumatic Agents / Q000009:adverse effects; D064420:Drug-Related Side Effects and Adverse Reactions; D004365:Drugs, Chinese Herbal / Q000009:adverse effects; D005260:Female; D006801:Humans; D008168:Lung / Q000000981:diagnostic imaging* / Q000473:pathology*; D008297:Male; D008727:Methotrexate / Q000009:adverse effects; D008875:Middle Aged; D050607:Organogold Compounds; D011014:Pneumonia / Q000139:chemically induced* / Q000145:classification / Q000473:pathology*; D014057:Tomography, X-Ray Computed
D000890:Anti-Infective Agents; D018501:Antirheumatic Agents; D004365:Drugs, Chinese Herbal; D050607:Organogold Compounds; D008727:Methotrexate